Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker

BrainStorm Cell Therapeutics has latched on to the recent accelerated FDA approval of Biogen and Ionis’ amyotrophic lateral sclerosis (ALS) drug to make the case that its cell therapy could join the rival product on the U.S. market.